LIT vs XBI
Global X Lithium & Battery Tech ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.75% for LIT.
- • LIT pays a higher dividend yield (0.84%).
Side-by-side metrics
| Metric | LIT | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.75% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.84% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $1.12B | $10.92B |
YTD return | -5.01% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.39 | 1.01 |
P/E ratio | 20.56 | — |
Last price | $61.29 | $156.41 |
Inception | — | — |
Issuer | Global X | State Street |
LIT top holdings
| RIO | Rio Tinto PLC ADR | 22.91% |
| 006400.KQ | Samsung SDI Co Ltd | 7.00% |
| 6752.T | Panasonic Holdings Corp | 6.68% |
| 002371.SZ | NAURA Technology Group Co Ltd Class A | 5.75% |
| TSLA | Tesla Inc | 5.73% |
| 6762.T | TDK Corp | 5.71% |
| 373220.KQ | LG Energy Solution Ltd | 4.93% |
| ALB | Albemarle Corp | 4.15% |
| 300014.SZ | EVE Energy Co Ltd Class A | 3.65% |
| 01211 | BYD Co Ltd Class H | 3.35% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About LIT
LIT (Global X Lithium & Battery Tech ETF) is Full lithium cycle from mining to battery production. Managed by Global X, the fund carries $1.1B in assets under management, an expense ratio of 0.75%, a dividend yield of 0.84%. Its largest holding is Rio Tinto PLC ADR (RIO), which represents 22.9% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 9.2%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.